Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: Application to emergence of lamivudine-resistant hepatitis B virus

Proceedings of the Royal Society B: Biological Sciences

Volumn 266, Issue 1436, 1999, Pages 2359-2366

  Burroughs, N J ^a   Pillay, D ^b   Mutimer, D ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Drug resistance; Hepatitis B; Hypothesis testing; Markov chain Monte Carlo; Virus dynamics

Indexed keywords

LAMIVUDINE;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL STUDY; DYNAMICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROBABILITY; SYSTEM ANALYSIS; VIROGENESIS; VIRUS CARRIER;

HEPATITIS B VIRUS;

EID: 0033534005     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.1999.0932     Document Type: Article

References (14)

1. Burroughs, N. J., Rand, D. A., Pillay, D., Elias, E. & Mutimer, D. 1998 The consequences of quasispecies heterogeneity and within-host ecology for antiviral therapy of hepatitis B virus. In Therapies for viral hepatitis (ed R. F. Schinazi, J. Sommadossi & H. C. Thomas), pp. 335-343. London: International Medical Press.
2. Cane, P. A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E. & Pillay, D. 1999 Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Therapy 4, 7-14.
3. Chayama, K. (and 14 others) 1998 Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-1716.
4. Davies, S. E., Portmann, B. C., O'Grady, J. G., Aldis, P. M., Chaggar, K., Alexander, G. J. M. & Williams, R. 1991 Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13, 150-158.
5. Gelman, A. & Meng, X.-L. 1996 Model checking and model improvement. In Markov chain Monte Carlo in practice, interdisciplinary statistics (ed. W. R. Gilks, S. Richardson & D. J. Spiegelhalter), pp. 189-201. London: Chapman & Hall.
6. Gilks, W. R., Clayton, D. G., Spiegelhalter, D. J., Best, N. G., McNeil, A. J., Sharples, L. D. & Kirby, A. J. 1993 Modeling complexity applications of Gibbs sampling in medicine. J. R. Statist. Soc. B 55, 39-52.
7. Gilks, W. R., Richardson, S. & Spiegelhalter, D. J. (eds) 1996 Markov chain Monte Carlo in practice, interdisciplinary statistics. London: Chapman & Hall.
8. Lai, C. L. (and 11 others) 1998 A one-year trial of lamivudine for chronic hepatitis B. New Engl. J. Med. 339, 61-68.
9. Leung, N. W. Y., Lai, C. L., Chang, T. T., Guan, R., Lee, C. M., Ng, K. Y., Wu, P. C., Dent, J. C., Edmundsen, S. & Liaw, Y. F. 1999 Three year lamivudine therapy in chronic HBV. J. Hepatol. 30, 59 (abstract).
10. McMillan, J. S., Shaw, T., Angus, P. W. & Locarnini, S. A. 1995 Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22, 36-43.
11. Mutimer, D. (and 16 others) 1999 High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 30, 715-721.
12. Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C. & McDade, H. 1996 Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93, 4398-4402.
13. Perrillo, R. (and 13 others) 1999 Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29, 1581-1586.
14. Spiegelhalter, D. J., Best, N. G., Gilks, W. R. & Inskip, H. 1996 Hepatitis B: a case study in MCMC methods. In Markov chain Monte Carlo in practice, interdisciplinary statistics (eds W. R. Gilks, S. Richardson & D. J. Spiegelhalter), pp. 21-43. London: Chapman & Hall.